CIK 1773195
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 88.80% | 75 |
| Unclassified | 10.06% | 12 |
| Health Care Equipment & Supplies | 1.13% | 5 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | APGE | Apogee Therapeutics, Inc. | Health Care | 6.45% |
| 2 | XENE | Xenon Pharmaceuticals Inc. | Health Care | 5.81% |
| 3 | ERAS | Erasca, Inc. | Health Care | 5.16% |
| 4 | INSM | INSMED Inc | Health Care | 4.68% |
| 5 | ROIV | Roivant Sciences Ltd. | Health Care | 4.63% |
| 6 | SYRE | Spyre Therapeutics, Inc. | Health Care | 3.85% |
| 7 | CENTESSA PHARMACEUTICALS PLC | Unclassified | 3.32% | |
| 8 | PRAX | Praxis Precision Medicines, Inc. | Health Care | 3.27% |
| 9 | ANAB | ANAPTYSBIO, INC | Health Care | 3.11% |
| 10 | ALKS | Alkermes plc. | Health Care | 2.85% |
80/92 names classified · sector 89.9% of weight · industry 89.9% · mkt cap 85.3%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 89.9% of the book is sector-classified (unclassified names shown, never dropped).
Only 5% of book weight classified — the grid is NOT representative of the whole book.
Classified: 5.5% of book weight (4/88 names) · unclassified 94.5%: , APGE, XENE, ERAS, INSM, ROIV, SYRE, PRAX, ANAB, CYTK +74 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | APGEAPOGEE THERAPEUTICS INC | 1,284,926 | $108M | 6.5% | ADD 4% |
| 2 | XENEXENON PHARMACEUTICALS INC | 1,675,000 | $97M | 5.8% | ADD 34% |
| 3 | ERASERASCA INC | 5,350,000 | $87M | 5.2% | ADD 37% |
| 4 | INSMINSMED INC | 480,000 | $78M | 4.7% | ADD 7% |
| 5 | ROIVROIVANT SCIENCES LTD | 2,800,000 | $78M | 4.6% | ADD 65% |
| 6 | SYRESPYRE THERAPEUTICS INC | 1,279,134 | $65M | 3.8% | TRIM −11% |
| 7 | CENTESSA PHARMACEUTICALS PLC | 1,400,000 | $56M | 3.3% | ADD 133% |
| 8 | PRAXPRAXIS PRECISION MEDICINES I | 170,000 | $55M | 3.3% | TRIM −8% |
| 9 | ANABANAPTYSBIO INC | 940,000 | $52M | 3.1% | ADD 111% |
| 10 | ALKSALKERMES PLC | 1,350,000 | $48M | 2.8% | ADD 35% |
| 11 | CYTKCYTOKINETICS INC | 700,483 | $46M | 2.8% | TRIM −12% |
| 12 | ABVXABIVAX SA | 405,000 | $45M | 2.7% | TRIM −20% |
| 13 | TEVATEVA PHARMACEUTICAL INDS LTD | 1,400,000 | $42M | 2.5% | HOLD |
| 14 | ARCELLX INC | 362,764 | $42M | 2.5% | TRIM −31% |
| 15 | NUVLNUVALENT INC | 300,000 | $31M | 1.8% | TRIM −7% |
| 16 | TERNS PHARMACEUTICALS INC | 562,631 | $30M | 1.8% | ADD 2% |
| 17 | DNTHDIANTHUS THERAPEUTICS INC | 350,000 | $29M | 1.8% | ADD 204% |
| 18 | LXEOLEXEO THERAPEUTICS INC | 5,050,211 | $29M | 1.7% | ADD 58% |
| 19 | COGTCOGENT BIOSCIENCES INC | 750,000 | $29M | 1.7% | ADD 114% |
| 20 | MDGLMADRIGAL PHARMACEUTICALS INC | 55,000 | $29M | 1.7% | ADD 77% |
| 21 | STROSUTRO BIOPHARMA INC | 1,069,519 | $27M | 1.6% | ADD 43% |
| 22 | FBRXFORTE BIOSCIENCES INC | 1,011,890 | $26M | 1.6% | ADD 2% |
| 23 | ORKAORUKA THERAPEUTICS INC | 499,673 | $25M | 1.5% | TRIM −38% |
| 24 | TRVITREVI THERAPEUTICS INC | 2,000,172 | $24M | 1.4% | TRIM −7% |
| 25 | OVIDOVID THERAPEUTICS INC | 10,636,318 | $24M | 1.4% | ADD 49% |
| 26 | ELVNENLIVEN THERAPEUTICS INC | 586,904 | $23M | 1.4% | NEW |
| 27 | ASNDASCENDIS PHARMA A/S | 95,000 | $22M | 1.3% | ADD 217% |
| 28 | MLYSMINERALYS THERAPEUTICS INC | 750,000 | $20M | 1.2% | ADD 3% |
| 29 | AVTXAVALO THERAPEUTICS INC | 1,340,840 | $20M | 1.2% | ADD 28% |
| 30 | PTGXPROTAGONIST THERAPEUTICS INC | 172,125 | $18M | 1.1% | HOLD |
| 31 | CLDXCELLDEX THERAPEUTICS INC NEW | 500,000 | $16M | 0.9% | ADD 43% |
| 32 | ZURAZURA BIO LTD | 2,564,303 | $15M | 0.9% | ADD 41% |
| 33 | NRIXNURIX THERAPEUTICS INC | 967,620 | $15M | 0.9% | HOLD |
| 34 | SVRASAVARA INC | 2,512,153 | $14M | 0.8% | TRIM −10% |
| 35 | CATXPERSPECTIVE THERAPEUTICS INC | 3,164,582 | $13M | 0.8% | ADD 955% |
| 36 | HLXCHELIX ACQUISITION CORP III | 1,250,000 | $13M | 0.8% | NEW |
| 37 | ARWRARROWHEAD PHARMACEUTICALS IN | 200,000 | $13M | 0.7% | ADD 186% |
| 38 | DMRADAMORA THERAPEUTICS INC | 450,000 | $12M | 0.7% | NEW |
| 39 | EPRXEupraxia Pharmaceuticals Inc | 1,589,005 | $12M | 0.7% | ADD 430% |
| 40 | ANROALTO NEUROSCIENCE INC | 500,000 | $11M | 0.7% | NEW |
| 41 | BBIOBRIDGEBIO PHARMA INC | 150,000 | $11M | 0.7% | TRIM −53% |
| 42 | CGEMCULLINAN THERAPEUTICS INC | 781,260 | $11M | 0.7% | TRIM −60% |
| 43 | BLTEBELITE BIO INC | 65,000 | $10M | 0.6% | ADD 225% |
| 44 | WVEWAVE LIFE SCIENCES LTD | 1,401,727 | $10M | 0.6% | TRIM −48% |
| 45 | VERAVERA THERAPEUTICS INC | 250,000 | $10M | 0.6% | HOLD |
| 46 | TYRATYRA BIOSCIENCES INC | 257,512 | $10M | 0.6% | NEW |
| 47 | RVMDREVOLUTION MEDICINES INC | 100,000 | $10M | 0.6% | HOLD |
| 48 | JBIOJADE BIOSCIENCES INC | 639,956 | $9M | 0.5% | TRIM −10% |
| 49 | TVTXTRAVERE THERAPEUTICS INC | 300,000 | $9M | 0.5% | HOLD |
| 50 | NAMSNEWAMSTERDAM PHARMA COMPANY | 275,000 | $9M | 0.5% | HOLD |
| 51 | KRROKORRO BIO INC | 706,904 | $8M | 0.5% | NEW |
| 52 | CRSPCRISPR THERAPEUTICS AG | 150,000 | $7M | 0.4% | NEW |
| 53 | SGPSPYGLASS PHARMA INC | 250,000 | $6M | 0.4% | NEW |
| 54 | CMPSCOMPASS PATHWAYS PLC | 1,108,483 | $6M | 0.4% | ADD 454% |
| 55 | IBIOIBIO INC | 3,107,200 | $6M | 0.4% | ADD 51% |
| 56 | ESTAESTABLISHMENT LABS HLDGS INC | 100,000 | $6M | 0.3% | TRIM −50% |
| 57 | AVRANTERIS TECHNOLOGIES GLOBAL | 912,397 | $5M | 0.3% | ADD 87% |
| 58 | NAMSWNEWAMSTERDAM PHARMA CO NV-27 | 245,000 | $5M | 0.3% | HOLD |
| 59 | VRDNVIRIDIAN THERAPEUTICS INC | 250,000 | $5M | 0.3% | HOLD |
| 60 | CLYMCLIMB BIO INC | 700,000 | $5M | 0.3% | TRIM −46% |
| 61 | RZLTREZOLUTE INC | 1,547,641 | $5M | 0.3% | TRIM −34% |
| 62 | SGMTSAGIMET BIOSCIENCES INC | 868,020 | $5M | 0.3% | TRIM −24% |
| 63 | MBXMBX BIOSCIENCES INC | 150,000 | $4M | 0.3% | TRIM −40% |
| 64 | TSHATAYSHA GENE THERAPIES INC | 1,000,000 | $4M | 0.3% | TRIM −70% |
| 65 | MANEVeradermics Inc | 70,000 | $4M | 0.3% | NEW |
| 66 | GENBGENERATE BIOMEDICINES INC | 350,000 | $4M | 0.3% | NEW |
| 67 | ENGENE HOLDINGS INC | 610,370 | $4M | 0.2% | TRIM −5% |
| 68 | AVBPARRIVENT BIOPHARMA INC | 175,000 | $4M | 0.2% | ADD 17% |
| 69 | RLAYRELAY THERAPEUTICS INC | 400,000 | $4M | 0.2% | NEW |
| 70 | PRQRPROQR THRAPEUTICS N V | 2,454,278 | $4M | 0.2% | HOLD |
| 71 | VRCAVERRICA PHARMACEUTICALS INC | 707,338 | $4M | 0.2% | HOLD |
| 72 | DTILPRECISION BIOSCIENCES INC | 597,946 | $3M | 0.2% | NEW |
| 73 | KPTIKARYOPHARM THERAPEUTICS INC | 500,000 | $3M | 0.2% | TRIM −44% |
| 74 | SLGLSOL GEL TECHNOLOGIES | 35,000 | $3M | 0.2% | NEW |
| 75 | CRNXCRINETICS PHARMACEUTICALS IN | 75,000 | $3M | 0.2% | HOLD |
| 76 | OACCUOAKTREE ACQUISITION CORP III | 250,000 | $3M | 0.2% | HOLD |
| 77 | NXTCNEXTCURE INC | 241,826 | $3M | 0.2% | TRIM −2% |
| 78 | IMVTIMMUNOVANT INC | 100,000 | $2M | 0.1% | TRIM −50% |
| 79 | EQEQUILLIUM INC | 1,226,310 | $2M | 0.1% | NEW |
| 80 | SABSSAB BIOTHERAPEUTICS INC | 575,000 | $2M | 0.1% | NEW |
| 81 | CORTCORCEPT THERAPEUTICS INC | 50,000 | $2M | 0.1% | NEW |
| 82 | OBIOORCHESTRA BIOMED HLDGS INC | 402,550 | $2M | 0.1% | TRIM −30% |
| 83 | KEZAR LIFE SCIENCES INC | 229,076 | $2M | 0.1% | HOLD |
| 84 | MGNXMACROGENICS INC | 500,000 | $1M | 0.1% | ADD 3% |
| 85 | ANLADLAI NORTYE LTD | 164,748 | $1M | 0.1% | NEW |
| 86 | ALECALECTOR INC | 500,000 | $1M | 0.1% | NEW |
| 87 | OKURONKURE THERAPEUTICS INC | 240,963 | $997,587 | 0.1% | NEW |
| 88 | LENZLENZ THERAPEUTICS INC | 100,000 | $915,000 | 0.1% | NEW |
| 89 | XFORX4 PHARMACEUTICALS INC | 145,000 | $598,850 | 0.0% | HOLD |
| 90 | QTTBQ32 BIO INC | 27,777 | $178,328 | 0.0% | HOLD |
| 91 | ADGMADAGIO MED HLDGS INC | 80,000 | $92,000 | 0.0% | HOLD |
| 92 | RCKTWWTS ROCKET PHARMACEUTICALS INC | 75,000 | $1,178 | 0.0% | HOLD |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| APGEAPOGEE THERAPEUTICS INC | 932K | 1.2M | 692K | 1.2M | 1.2M | 1.3M | $108M |
| XENEXENON PHARMACEUTICALS INC | 1.2M | 1.3M | 1.1M | 1.4M | 1.3M | 1.7M | $97M |
| ERASERASCA INC | 2.5M | 3.3M | 4.1M | 4.3M | 3.9M | 5.3M | $87M |
| INSMINSMED INC | 50K | 140K | 475K | 450K | 450K | 480K | $78M |
| ROIVROIVANT SCIENCES LTD | — | 150K | 400K | 800K | 1.7M | 2.8M | $78M |
| SYRESPYRE THERAPEUTICS INC | 824K | 482K | 607K | 1.4M | 1.4M | 1.3M | $65M |
| CENTESSA PHARMACEUTICALS PLC | 1.1M | 1.5M | 900K | 1.1M | 601K | 1.4M | $56M |
| PRAXPRAXIS PRECISION MEDICINES I | — | — | — | — | 185K | 170K | $55M |
| ANABANAPTYSBIO INC | — | — | — | — | 445K | 940K | $52M |
| ALKSALKERMES PLC | 1.1M | 1.0M | 1.0M | 1.3M | 1.0M | 1.4M | $48M |
| CYTKCYTOKINETICS INC | — | — | — | 350K | 800K | 700K | $46M |
| ABVXABIVAX SA | — | 200K | 100K | 360K | 505K | 405K | $45M |
| TEVATEVA PHARMACEUTICAL INDS LTD | 1.4M | 1.4M | 1.4M | 1.4M | 1.4M | 1.4M | $42M |
| ARCELLX INC | 425K | 530K | 495K | 500K | 524K | 363K | $42M |
| NUVLNUVALENT INC | 285K | 460K | 415K | 384K | 323K | 300K | $31M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
